Tamara van Donge1, Anne Smits2,3, John van den Anker1,4, Karel Allegaert2,5,6. 1. Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, 4001 Basel, Switzerland. 2. Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium. 3. Neonatal Intensive Care Unit, University Hospitals Leuven, 3000 Leuven, Belgium. 4. Division of Clinical Pharmacology, Children's National Health Hospital, Washington, DC 20010, USA. 5. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium. 6. Department of Hospital Pharmacy, Erasmus MC University Medical Center, 3015 Rotterdam, The Netherlands.
Abstract
BACKGROUND: Disentangling renal adverse drug reactions from confounders remains a major challenge to assess causality and severity in neonates, with additional limitations related to the available tools (modified Kidney Disease Improving Global Outcome, or Division of Microbiology and Infectious Diseases pediatric toxicity table). Vancomycin and amikacin are nephrotoxic while still often prescribed in neonates. We selected these compounds to assess their impact on creatinine dynamics as a sensitive tool to detect a renal impairment signal. METHODS: A recently developed dynamical model that characterized serum creatinine concentrations of 217 extremely low birth weight (<1000 g, ELBW) neonates (4036 observations) was enhanced with data on vancomycin and/or amikacin exposure to identify a potential effect of antibiotic exposure by nonlinear mixed-effects modelling. RESULTS: Seventy-seven percent of ELBW patients were exposed to either vancomycin or amikacin. Antibiotic exposure resulted in a modest increase in serum creatinine and a transient decrease in creatinine clearance. The serum creatinine increase was dependent on gestational age, illustrated by a decrease with 56% in difference in serum creatinine between a 24 or 32-week old neonate, when exposed in the 3rd week after birth. CONCLUSIONS: A previously described model was used to explore and quantify the impact of amikacin or vancomycin exposure on creatinine dynamics. Such tools serve to explore minor changes, or compare minor differences between treatment modalities.
BACKGROUND: Disentangling renal adverse drug reactions from confounders remains a major challenge to assess causality and severity in neonates, with additional limitations related to the available tools (modified Kidney Disease Improving Global Outcome, or Division of Microbiology and Infectious Diseases pediatric toxicity table). Vancomycin and amikacin are nephrotoxic while still often prescribed in neonates. We selected these compounds to assess their impact on creatinine dynamics as a sensitive tool to detect a renal impairment signal. METHODS: A recently developed dynamical model that characterized serum creatinine concentrations of 217 extremely low birth weight (<1000 g, ELBW) neonates (4036 observations) was enhanced with data on vancomycin and/or amikacin exposure to identify a potential effect of antibiotic exposure by nonlinear mixed-effects modelling. RESULTS: Seventy-seven percent of ELBW patients were exposed to either vancomycin or amikacin. Antibiotic exposure resulted in a modest increase in serum creatinine and a transient decrease in creatinine clearance. The serum creatinine increase was dependent on gestational age, illustrated by a decrease with 56% in difference in serum creatinine between a 24 or 32-week old neonate, when exposed in the 3rd week after birth. CONCLUSIONS: A previously described model was used to explore and quantify the impact of amikacin or vancomycin exposure on creatinine dynamics. Such tools serve to explore minor changes, or compare minor differences between treatment modalities.
Authors: Robert M Ward; Daniel Benjamin; Jeffrey S Barrett; Karel Allegaert; Ronald Portman; Jonathan M Davis; Mark A Turner Journal: Pediatr Res Date: 2016-11-03 Impact factor: 3.756
Authors: Esther J H Janssen; Pyry A J Välitalo; Karel Allegaert; Roosmarijn F W de Cock; Sinno H P Simons; Catherine M T Sherwin; Johan W Mouton; Johannes N van den Anker; Catherijne A J Knibbe Journal: Antimicrob Agents Chemother Date: 2015-12-07 Impact factor: 5.191
Authors: Thomas Salaets; Mark A Turner; Mary Short; Robert M Ward; Isamu Hokuto; Ronald L Ariagno; Agnes Klein; Sandra Beauman; Kelly Wade; Merran Thomson; Eve Roberts; Judy Harrison; Theresa Quinn; Gerri Baer; Jonathan Davis; Karel Allegaert Journal: Arch Dis Child Date: 2019-09-19 Impact factor: 3.791
Authors: Sara N Salerno; Yuting Liao; Wesley Jackson; Rachel G Greenberg; Cameron J McKinzie; Ashley McCallister; Daniel K Benjamin; Matthew M Laughon; Keia Sanderson; Reese H Clark; Daniel Gonzalez Journal: J Pediatr Date: 2020-08-17 Impact factor: 4.406